Richard T. Silver

25.4k total citations · 1 hit paper
227 papers, 8.3k citations indexed

About

Richard T. Silver is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Richard T. Silver has authored 227 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Genetics, 130 papers in Hematology and 79 papers in Rheumatology. Recurrent topics in Richard T. Silver's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (106 papers), Chronic Myeloid Leukemia Treatments (86 papers) and Eosinophilic Disorders and Syndromes (77 papers). Richard T. Silver is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (106 papers), Chronic Myeloid Leukemia Treatments (86 papers) and Eosinophilic Disorders and Syndromes (77 papers). Richard T. Silver collaborates with scholars based in United States, United Kingdom and France. Richard T. Silver's co-authors include Hagop M. Kantarjian, Andreas Hochhaus, Michael W. Deininger, Timothy P. Hughes, Jane F. Apperley, Francisco Cervantes, Rüdiger Hehlmann, Dietger Niederwieser, Michele Baccarani and François Guilhot and has published in prestigious journals such as Nature, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Richard T. Silver

220 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

2009 890 citations Michael W. Deininger, Richard T. Silver et al. profile →

Peers

Countries citing papers authored by Richard T. Silver

Since Specialization

Citations

This map shows the geographic impact of Richard T. Silver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard T. Silver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard T. Silver more than expected).

Fields of papers citing papers by Richard T. Silver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard T. Silver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard T. Silver. The network helps show where Richard T. Silver may publish in the future.

Co-authorship network of co-authors of Richard T. Silver

This figure shows the co-authorship network connecting the top 25 collaborators of Richard T. Silver. A scholar is included among the top collaborators of Richard T. Silver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard T. Silver. Richard T. Silver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes 2024 ·Blood Advances ·(unknown), Oleksandr Savenkov, (unknown), (unknown), Richard T. Silver, Nicole Kucine, Joseph M. Scandura, Ghaith Abu‐Zeinah	4
2	A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis 2024 ·Annals of Hematology ·Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa	3
3	Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival 2022 ·Leukemia ·Richard T. Silver, (unknown), (unknown), Joseph M. Scandura, Ghaith Abu‐Zeinah	1
4	Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome 2022 ·Blood Advances ·Ghaith Abu‐Zeinah, Silvana Di Giandomenico, Daniel Choi, (unknown), (unknown), (unknown), Ellen K. Ritchie, Richard T. Silver, Joseph M. Scandura	4
5	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival 2021 ·Leukemia ·Ghaith Abu‐Zeinah, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ellen K. Ritchie, Joseph M. Scandura, Richard T. Silver	61
6	Normal life expectancy for polycythemia vera (PV) patients is possible 2021 ·Leukemia ·Ghaith Abu‐Zeinah, Richard T. Silver, (unknown), Joseph M. Scandura	26
7	A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients 2021 ·Blood ·Ghaith Abu‐Zeinah, (unknown), Richard T. Silver, (unknown), Douglas Tremblay, Andrew Srisuwananukorn, John Mascarenhas, Joseph M. Scandura	3
8	Normal Life Expectancy for Polycythemia Vera Patients Is Possible 2021 ·Blood ·Ghaith Abu‐Zeinah, Richard T. Silver, (unknown), Joseph M. Scandura	2
9	Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values 2019 ·Haematologica ·Richard T. Silver, (unknown)	14
10	Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib 2017 ·Blood ·Ellen K. Ritchie, (unknown), Gail J. Roboz, Richard T. Silver, Andrew I. Schafer, Joseph M. Scandura, Pinkal Desai, Sang‐Min Lee, Michael Samuel	2
11	Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate 2007 ·Current Hematologic Malignancy Reports ·Richard T. Silver	1
12	Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease 2006 ·Cancer Research ·Thomas G.P. Bumm, Collin Elsea, Amie S. Corbin, Marc Loriaux, Daniel W. Sherbenou, Lisa J. Wood, Jutta Deininger, Richard T. Silver, Brian Druker, Michael W. Deininger	151
13	An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions 2006 ·The Journal of Immunology ·Zeyu Xiong, Enli Liu, Yan Yan, Richard T. Silver, Fan Yang, (unknown), Yangyang Chen, Srđan Verstovšek, Hong Wang, Josef T. Prchal, Xiaofeng Yang	25
14	A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy 2006 ·Biology of Blood and Marrow Transplantation ·Tsiporah B. Shore, John G. Harpel, Michael W. Schuster, Gail J. Roboz, John P. Leonard, Morton Coleman, Eric J. Feldman, Richard T. Silver	9
15	Effect of hematocrit on platelet adhesion under arterial flow conditions 2003 ·Blood ·Ellinor I.B. Peerschke, Babette B. Weksler, Richard T. Silver, Naphtali Savion, David Varon	1
16	Chronic myeloid leukemia 2003 ·Hematology/Oncology Clinics of North America ·Richard T. Silver	18
17	Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors 1998 ·Annals of Oncology ·Alice B. Kornblith, James E. Herndon, E Zuckerman, David Cella, Eva Cherin, (unknown), R B Weiss, Louis F. Diehl, E. S. Henderson, M. Robert Cooper, CA Schiffer, George P. Canellos, Robert J. Mayer, Richard T. Silver, Andrea Schilling, B. A. Peterson, Dan Greenberg, Jimmie C. Holland	71
18	Combination trial of subcutaneous recombinant α₂b interferon and oral cyclophosphamide in follicular low‐grade non‐Hodgkin's lymphoma 1994 ·Medical and Pediatric Oncology ·Howard Ozer, James R. Anderson, B. A. Peterson, Daniel R. Budman, M. Robert Cooper, B. J. Kennedy, Richard T. Silver, Edward S. Henderson, David B. Duggan, (unknown), Clara D. Bloomfield, Arlan J. Gottlieb	11
19	Attempted Prevention of Blast Crisis in Chronic Myeloid Leukemia by the Use of Pulsed Doses of Cytosine Arabinoside and cis-Chloronitrosurea During the Course of Busulfan-Maintained Remission 1988 ·Cancer Investigation ·Richard T. Silver, Rosemarie Mick, Thomas J. Degnan, James F. Holland, (unknown)	4
20	Association of Hodgkin disease and Gaucher disease 1974 ·Archives of Pathology & Laboratory Medicine ·Leroy R. Sharer, Jeremiah A. Barondess, Richard T. Silver, George F. Gray	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact